Home
XIIDRA

XIIDRA Market Share Analysis for November 2025

discover xiidra, a prescription eye drop treatment that can help provide lasting relief for dry eye disease. see full prescribing and safety info.

Health > Pharmacy

Domainxiidra.com

Year Founded2016

Employees501 - 1000

Annual Revenue$200M - $500M

XIIDRA

XIIDRA (including company regionals)

xiidra.com

See more website traffic and engagement information

XIIDRA Revenue up to November 2025 is 200M - 500M

revenue generated by XIIDRA top domains

XIIDRA top domains revenue over 3 years

Revenue for XIIDRA top domains

xiidra.com200M - 500M

See more with Sales Intelligence

Total visits to XIIDRA's top domains

Understand XIIDRA market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

xiidra.com53K

See more with Sales Intelligence

Avg. visit duration in XIIDRA's top domains

Analyze XIIDRA engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

xiidra.com00:00:39

See more with Sales Intelligence

Avg. pageviews on XIIDRA's top domains

See how XIIDRA keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

xiidra.com1.53

See more with Sales Intelligence

XIIDRA top competitors by domain

Top similar sites in November 2025, ranked by their affinity

zyrtec.comCompany NameZyrtecEmployees51 - 200HQUnited States, California, Redondo BeachAnnual revenue$200M - $500MTotal visits139.4KHealth > Pharmacy

Top technologies used by XIIDRA

These are the website technologies, by industry, used by XIIDRA top domains

Advertising (26)

DoubleClick

Conversion & Analytics (8)

Google Analytics

Audio Video Media (6)

YouTube

Marketing (5)

Google Marketing Platform

More Technologies

6

See all

News & Signals from XIIDRA

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBausch Health acquires Xiidra for $2.5B.Bausch Health's Bausch + Lomb announces completion of the acquisition of XIIDRA(R).

Newslumifyeyes acquires Xiidra for $2.5B.The deal comes less than a week after Bausch + Lomb entered into a definitive to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution 5%) from Novartis in a deal worth up to $2.5 billion, including an upfront payment of $1.75 billion in cash.

NewsBausch & Lomb Incorporated acquired Xiidra for $2.5B on Jun 30th '23.Under the agreement, Bausch + Lomb acquires Xiidra, libvatrep, AcuStream, and OJL332 from Novartis for up to $2.5 billion.